Does PEMBROLIZUMAB Cause Hepatic neoplasm? 11 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Hepatic neoplasm have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.0% of all adverse event reports for PEMBROLIZUMAB.
11
Reports of Hepatic neoplasm with PEMBROLIZUMAB
0.0%
of all PEMBROLIZUMAB reports
2
Deaths
5
Hospitalizations
How Dangerous Is Hepatic neoplasm From PEMBROLIZUMAB?
Of the 11 reports, 2 (18.2%) resulted in death, 5 (45.5%) required hospitalization.
Is Hepatic neoplasm Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 11 reports have been filed with the FAERS database.
What Other Side Effects Does PEMBROLIZUMAB Cause?
Malignant neoplasm progression (10,111)
Death (4,744)
Diarrhoea (4,251)
Fatigue (3,833)
Off label use (3,416)
Product use in unapproved indication (3,191)
Pyrexia (3,155)
Rash (2,900)
Nausea (2,670)
Decreased appetite (2,486)
What Other Drugs Cause Hepatic neoplasm?
OCTREOTIDE (300)
ADALIMUMAB (98)
LANREOTIDE (85)
EVEROLIMUS (84)
AMLODIPINE (74)
ROSUVASTATIN (55)
IMATINIB (51)
BEVACIZUMAB (49)
RIBAVIRIN (49)
METFORMIN (47)
Which PEMBROLIZUMAB Alternatives Have Lower Hepatic neoplasm Risk?
PEMBROLIZUMAB vs PEMETREXED
PEMBROLIZUMAB vs PEMIGATINIB
PEMBROLIZUMAB vs PENICILLAMINE
PEMBROLIZUMAB vs PENICILLIN
PEMBROLIZUMAB vs PENICILLIN G